Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2016 13:16 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement

Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced...
July 15, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock

GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock...
July 11, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio

GAITHERSBURG, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics...
June 27, 2016 09:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine

GAITHERSBURG, Md., June 27, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has...
June 22, 2016 08:32 ET | Source: Emergent BioSolutions Inc.

U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines

GAITHERSBURG, Md., June 22, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that on June 21, 2016, the U.S. Department of Health and Human Services (HHS) issued two...
June 21, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThrax

GAITHERSBURG, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval...
June 17, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s...
June 15, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

GAITHERSBURG, Md., June 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug status for...
May 05, 2016 16:15 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Reports First Quarter 2016 Financial Results

Q1 2016 financial performance in line with guidanceCDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on October 1, 2016In transitioning to the follow-on...
May 04, 2016 16:15 ET | Source: Emergent Biosolutions, Inc.

Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available

GAITHERSBURG, May 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM...